Overview of Capitol Health Limited's proposed merger with Integral Diagnostics Limited

Capitol Health Limited (ASX:CAJ) has released a Scheme Booklet registered with ASIC regarding the proposed merger with Integral Diagnostics Limited (ASX:IDX). The Scheme Booklet provides detailed information for Capitol shareholders to consider before voting on the proposed merger. The Scheme Booklet includes the notice of meeting for the Scheme Meeting and a copy of the Independent Expert's Report prepared by KPMG Financial Advisory Services, concluding that the Scheme is fair and reasonable and in the best interests of shareholders, in the absence of a superior proposal.

Executive Commentary on the Proposed Merger

The Scheme Booklet provides Capitol shareholders with comprehensive information about the proposed merger with Integral Diagnostics Limited, enabling them to make an informed decision when voting on the Scheme.

Outlook and Key Points of the Proposed Merger

Capitol Health Limited has released a Scheme Booklet outlining the merger with Integral Diagnostics (IDX) to create a leader in diagnostic imaging in Australia and New Zealand. The merger will result in a Merged Group with a footprint of 151 clinics and approximately 3,000 employees. The Merged Group is expected to have increased capacity to invest in higher-end imaging modalities and leverage IDX's teleradiology capabilities. The merger is expected to bring about at least $10 million of anticipated annual pre-tax net cost synergies. The Scheme Booklet provides detailed information on the merger and the potential risks and benefits associated with the creation of the Merged Group. Investors and stakeholders are advised to carefully consider the information provided before making any decisions related to the Scheme.